

References

- Adams, L.A.; Bulsara, M.; Rossi, E. et al., (2005):** Hepascore: An Accurate Validated Predictor of Liver Fibrosis in Chronic Hepatitis C Infection. *Clin Chem.*; 51: 1867–73
- Ala-Kokko, L.; Stenback, F.; Ryhanen, L. (1989):** Preventive effect of malotilate on dimethylnitrosamine-induced liver fibrosis in the rat. *J Lab Clin Med*; 113:177.
- Alison MR, Poulson R, and Jeffery R et al., (2000):** Hepatocytes from non-hepatic adult stem cells. *Nature*; 406:257.
- Arthur MJ (2000):** Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. *Am.J.Physiol. Gastrointest. Liver Physiol.*; 279:G245-G249.
- Bachem M. G., Melchior R. and Gressner A. M. (1989):** The role of thrombocytes in liver fibrogenesis: effects of platelet lysate and thrombocyte-derived growth factors on the mitogenic activity and glycosaminoglycan synthesis of cultured rat liver fat storing cells. *J. Clin. Chem. Clin. Biochem.*; 27: 555-565.
- Braet F, De Zanger R, Baekeland M et al., (1995):** Structure and dynamics of the fenestrae-associated cytoskeleton of rat liver sinusoidal endothelial cells. *Hepatology*; 21: 180.
- Bataller, R.; Schwabe, R.F.; Choi, Y.H.; et al., (2003):** NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. *J Clin Invest*; 112:1383–1394.
- Bedossa, P. & Poynard, T. (1996):** The French METAVIR Cooperative Study Group. An algorithm for grading activity in chronic hepatitis C. *Hepatology* ;24:289–293.

- Bioulac-Sage P, Lafon ME, Saric J et al., (1990):** Nerves and perisinusoidal cells in human liver. *J Hepatol.*; 10:105.
- Boetticher, N.C.; Peine, C.J.; Kwo, P. et al., (2008):** A randomized, double-blinded, placebocontrolled multicenter trial of etanercept in the treatment of alcoholic hepatitis. *Gastroenterology*;135:1953.
- Bonnard, P.; Lescure, F.X.; Amiel, C.; et al., (2007):** Documented rapid course of hepatic fibrosis between two biopsies in patients coinfectd by HIV and HCV despite high CD4 cell count. *J Viral Hepat*;14:806–811.
- Borkham-Kamphorst, E.; Stoll, D.; Gressner, A.M. et al., (2004):** Antisense strategy against PDGF B-chain proves effective in preventing experimental liver fibrogenesis. *Biochem Biophys Res Commun* ; 321:413.
- Borkham-Kamphorst, E.; Van-Roeyen, C.R.; Ostendorf, T.; et al., (2007):** Pro-fibrogenic potential of PDGF-D in liver fibrosis. *J Hepatol*; 46:1064 1074.
- Cales, P.; Oberti, F.; Michalak, S. et al.,(2005):** A novel panel of blood markers to assess the degree of liver fibrosis. *Hepatology.* ; 42: 1373–81.
- Caligiuri, A.; Bertolani, C.; Guerra, C.T. et al., (2008):** Adenosine monophosphate-activated protein kinase modulates the activated phenotype of hepatic stellate cells. *Hepatology*; 47:668.
- Canbay, A.; Kip, S.N.; Kahraman, A. et al., (2005):** Apoptosis and fibrosis in non-alcoholic fatty liver disease. *Turk J Gastroenterol* ; 16:1.
- Casini A., Ceni E. and Salzano R. (1997):** Neutrophil-derived superoxide anion induces lipid peroxidation and stimulates collagen

synthesis in human hepatic stellate cells: role of nitric oxide. *Hepatology*; 25: 361-367.

Castera, L.; Forns, X. and Alberti, A. (2008): Non-invasive evaluation of liver fibrosis using transient elastography. *J Hepatol*;48(5): 835–847.

Chan, E.S.; Montesinos, M.C.; Fernandez, P. et al., (2006): Adenosine A(2A) receptors play a role in the pathogenesis of hepatic cirrhosis. *Br J Pharmacol* ;148:1144–1155.

Chen, C.H.; Kuo, L.M.; Chang, Y.; et al., (2006): In vivo immune modulatory activity of hepatic stellate cells in mice. *Hepatology* ;44: 1171 **1181.**

Coco, B.; Oliveri, F.; Maina, A.M. et al., (2007): Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. *J Viral Hepatology*; 14:360–369.

Dekel, R.; Zvibel, I.; Brill, S. et al., (2003): Gliotoxin ameliorates development of fibrosis and cirrhosis in a thioacetamide rat model. *Dig Dis Sci* ; 48:1642.

Desmet, V.J.; Gerber, M.; Hoofnagel, J.H. et al., (1994): Classification of chronic hepatitis: diagnosis, grading and staging. *Hepatology*; 19:1513–1520.

De Minicis, S. and Brenner, D.A. (2007): NOX in liver fibrosis. *Arch Biochem Biophys* ;462:266–272.

Di Bisceglie, A.M.; Shiffman, M.L.; Everson, G.T. et al., (2008): Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. *N Engl J Med* ; 359:2429.

DON, C. (2008): Noninvasive Assessment of Liver Fibrosis and Portal Hypertension with Transient Elastography *Gastroenterology*; 134:8–14

Dooley, S.; Delvoux, B.; Lahme, B. et al., (2000): Modulation of transforming growth factor beta response and signalling during transdifferentiation of rat hepatic stellate cells to myofibroblasts. *Hepatology* ; 31: 1094–106.

Dooley, S.; Hamzavi, J.; Breitkopf, K. et al., (2003): Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats. *Gastroenterology* ; 125:178.

Duffield, J.S.; Forbes, S.J.; Constandinou, C.M.; et al., (2005): Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. *J Clin Invest*; 115:56–65.

Dunn, M.A.; Rojkind, M.; Warren, K.S.; et al. (1977): Liver collagen synthesis in murine schistosomiasis. *J Clin Invest* ; 59: 666-74.

Fallowfield, J.A. & Iredale, J.P. (2004): Targeted treatments for cirrhosis. *Expert Opin Ther Targets* ; 8:423.

Farci, P.; Roskams, T.; Chessa, L. et al., (2004): Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. *Gastroenterology*; 126:1740–1749.

Ferenci, P.; Dragosics, B.; Dittrich, H. et al., (1989): Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. *J Hepatol* ; 9:105.

Fiorucci, S.; Antonelli, E.; Rizzo, G. et al., (2004): The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. *Gastroenterology* ; 127:1497.

- Flisiak, R.; Pytelkrolczuk, B. and Prokopowicz, D. (2000):** Circulating transforming growth factor beta(1) as an indicator of hepatic function impairment in liver cirrhosis. *Cytokine* ; 12: 677–81.
- Forbes S. J., Russo F. P., Rey V., et al. (2004):** A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. *Gastroenterology*; 126: 955-963.
- Fraquelli, M.; Rigamonti, C.; Conte, D. et al., (2007):** Reproducibility of transient elastography (TE) in assessing hepatic fibrosis. *Gut* ;56:968–973.
- Friedman, S.L. (1999):** Cytokines and fibrogenesis. *Semin Liver Dis*; 19:129.
- Friedman, S.L. (2000):** Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. *J Biol Chem* ;275: 2247–2250.
- Friedman, S.L. (2001):** *The Hepatic Stellate Cell*, Vol. 21. New York: Thieme, 2001.
- Friedman, S.L. (2003):** Liver fibrosis – from bench to bedside. *J Hepatol*; 38: s38–53.
- Friedman, S.L. (2004):** Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications. *Nat Clin Pract Gastroenterol Hepatol* ; 1:98.
- Friedman, S.L. (2008):** Hepatic stellate cells—protean, multifunctional ,and enigmatic cells of the liver. *Physiol Rev*;88:125–172.
- Friedman, S.L. (2008):** Mechanisms of Hepatic Fibrogenesis
GASTROENTEROLOGY ;134:1655–1669

Friedrich-Rust, M.; Ong, M.F.; Herrmann, E. et al., (2007): Real-time elastography for non-invasive assessment of liver fibrosis in chronic viral hepatitis. *AJR Am J Roentgenol* ;188:758–764.

Fritz, G.A.; Schoellnast, H.; Deutschmann, H.A. et al., (2006): Density histogram analysis of unenhanced hepatic computed tomography in patients with diffuse liver diseases. *J Comput Assist Tomogr* ;30:201–205.

Gao, R. and Brigstock, D.R. (2004): Connective tissue growth factor (CCN2) induces adhesion of rat activated hepatic stellate cells by binding of its C-terminal domain to integrin $\alpha(v)\beta(3)$ and heparan sulfate proteoglycan. *J Biol Chem* ;279:8848– 8855.

Geerts, A. & Rogiers, V. (1999): Sho-saiko-To: the right blend of traditional Oriental medicine and liver cell biology [editorial; comment]. *Hepatology* ; 29:282.

Geerts A. (2001): History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. *Semin Liver Dis*; 21: 311.

Gelfand, E.V. & Cannon, C.P. (2006): Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors. *Expert Opin Investig Drugs* ; 15:307.

Gressner, A.M. and Weiskirchen, R. (2006): Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. *J. Cell Mol. Med.*;10: 76–99.

Gressner, A.M.; Yagmur, E.; Lahme, B. et al., (2006): Connective tissue growth factor in serum as a new candidate test for assessment of hepatic fibrosis. *Clin Chem*: 52: 1815–7.

Gressner, O.A.; Lahme, B.; Demirci, I.; et al., (2007): Differential effects of TGF-beta on connective tissue growth factor (CTGF/CCN2) expression in hepatic stellate cells and hepatocytes. J Hepatol;47:699–710.

Gressner, O.A.; Weiskirchen, R., and Gressner, A.M. (2007): Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality. J. Cell. Mol. Med. Vol ;11,5:1031–1051.

Grove, J.; Daly, A.K.; Bassendine, M.F. et al., (2000): Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease. Gut. ; 46: 540–5.

Guéchet, J.; Poupon, R.E. and Poupon, R. (1995): Serum hyaluronan as a marker of liver fibrosis. J Hepatol ; 22: 103–6.

Guo, J. and Friedman, S.L. (2007): Hepatic fibrogenesis. Semin Liver Dis; 27: 413–26.

Guyot, C.; Combe, C.; Balabaud, C.; et al., (2007): Fibrogenic cell fate during fibrotic tissue remodelling observed in rat and human cultured liver slices. J Hepatol ;46:142–150.

Han, Y.P.; Yan, C.; Zhou, L.; et al., (2007): A matrix metalloproteinase-9 activation cascade by hepatic stellate cells in trans-differentiation in the three-dimensional extracellular matrix. J Biol Chem ;282:12928–12939.

Harmeet, M. and Gregory, J.G. (2007): Mechanisms of Liver Injury. In: Schiff's disease of the liver, 10th edition, edited by: Schiff, E.R.; Sorrell, M.F., Maddrey, W.C. Lippincott Williams & Wilkins, 1,14: 313-328.

- Hashimoto, K.; Murakami, T.; Dono, K. et al., (2006):** Assessment of the severity of liver disease and fibrotic change: the usefulness of hepatic CT perfusion imaging. *Oncol Rep* ;16:677–683.
- Hautekeete ML, Geert A, Seynaeve C, et al., (1993):** Contributions of light and transmission electron microscopy to the study of human fat storing cell. *Eur. J. Morphol.*; 31:72-76.
- Inagaki, Y. and Okazaki, I. (2007):** Emerging insights into transforming growth factor beta Smad signal in hepatic fibrogenesis. *Gut* ;56: 284–292.
- Iredale, J.P. (2007):** Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. *J Clin Invest* ;117:539–548.
- Ishak, K. et al., (1995):** Histological grading and staging of chronic hepatitis. *J Hepatol* ;22:696-699.
- Issa, R.; Zhou, X.; Constandinou, C.M. et al., (2004):** Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. *Gastroenterology*;126:1795–1808.
- Issa, R.; Zhou, X.; Trim, N.; et al., (2003):** Mutation in collagen-1 that confers resistance to the action of collagenase results in failure of recovery from CCl4-induced liver fibrosis, persistence of activated hepatic stellate cells, and diminished hepatocyte regeneration. *FASEB J* ;17:47–9.
- Iwamoto, H.; Sakai, H.; Tada, S.; et al., (1999):** Induction of apoptosis in rat hepatic stellate cells by disruption of integrin-mediated cell adhesion. *J Lab Clin Med* ; 134:83.

Jacobs, B.P.; Dennehy, C.; Ramirez, G. et al., (2002): Milk thistle for the treatment of liver disease. A systematic review and meta-analysis. *Am J Med* ; 113:506.

Jaeschke, H. (2006): Mechanisms of liver injury. II. Mechanisms of neutrophil-induced liver cell injury during hepatic ischemia-reperfusion and other acute inflammatory conditions. *Am J Physiol* ;290:G1083–G1088.

Jaeschke, H.; Gujral, J.S. and Bajt, M.L. (2004): Apoptosis and necrosis in liver disease. *Liver Int* ;24:85–89.

Jeong, W.I.; Park, O. and Gao, B. (2008): Abrogation of the anti-fibrotic effects of natural killer cells/interferon gamma contributes to alcohol acceleration of liver fibrosis. *Gastroenterology* ;134:248– 258.

Jeong, W.I.; Park, O.; Gao, B. et al., (2008): Abrogation of the antifibrotic effects of natural killer cells/interferon-gamma contributes to alcohol acceleration of liver fibrosis. *Gastroenterology*;134:248.

Jungermann K and Kietzmann T, (2000): Oxygen: modulator of metabolic zonation and disease of the liver. *Hepatology*; 31:255.

Kawada, N.; Seki, S.; Inoue, M. et al., (1998): Effect of antioxidants, resveratrol, quercetin, and N-acetylcysteine, on the functions of cultured rat hepatic stellate cells and Kupffer cells. *Hepatology* ; 27:1265.

Kim, W.H.; Matsumoto, K.; Bessho, K. et al., (2005): Growth inhibition and apoptosis in liver myofibroblasts promoted by hepatocyte growth factor leads to resolution from liver cirrhosis. *Am J Pathol* ; 166:1017.

Kisseleva, T.; Uchinami, H.; Feirt, N.; et al., (2006): Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. *J Hepatol* ;45:429–438.

Knittel T, Kobold D, Saile B et al., (1999): Rat liver myofibroblasts and hepatic stellate cells: different cell populations of the fibroblast lineage with fibrogenic potential. *Gastroenterology*; 117(5): 1244-1246.

Knodell, R.G. et al., (1981): Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. *Hepatology*;1(5):431-5

Koda, M.; Matunaga, Y.; Kawakami, M. et al., (2007): FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. *Hepatology.* ; 45: 297–306.

Kordes, C.; Sawitza, I.; Muller-Marbach, A.; et al., (2007): CD133_ hepatic stellate cells are progenitor cells. *Biochem Biophys Res Commun* ;352:410 – 417.

Laleman, W.; Van-Landeghem, L.; Severi, T.; et al., (2007): Both Ca²⁺-dependent and -independent pathways are involved in rat hepatic stellate cell contraction and intrahepatic hyperresponsiveness to methoxamine. *Am J Physiol Gastrointest Liver Physiol*;292:G556–G564.

Lee, J.S.; Semela, D.; Iredale, J.; et al., (2007): Sinusoidal remodeling and angiogenesis: a new function for the liver- specific pericyte? *Hepatology* ;45:817–825.

Lydatakis, H.; Hager, I.P.; Kostadelou, E.; et al., (2006): Non-invasive markers to predict the liver fibrosis in non-alcoholic fatty liver disease. *Liver Int.* ; 26: 864–71.

Magness S.T, Bataller R., Yang L., et al. (2004): A dual transporter gene in transgenic mouse demonstrates heterogeneity in hepatic fibrogenic cell populations. *Hepatology*; 40: 1151-1159.

Mallat A.; Teixeira-Clerc, F.; Deveaux, V.; et al., (2007): Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases. *Expert Opin Ther Targets* ;11:403–409.

Martino, V.D.; Lebray, P.; Myers, R.P. et al., (2004): Progression of liver fibrosis in women infected with hepatitis C: Long-term benefit of estrogen exposure. *Hepatology* ;40:1426–1433.

Massimo, P. and Francesco, V. (2008): Fibrosis and Cirrhosis Reversibility: Clinical Features and Implications. *Clin Liver Dis* ;12:901–913.

Melton, A.C. and Yee, H.F. (2007): Hepatic stellate cell protrusions couple platelet-derived growth factor-BB to chemotaxis. *Hepatology* ;45:1446–1453.

Melhem, A.; Muhanna, N.; Bishara, A. et al., (2006): Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. *J Hepatol* ; 45:60.

Munoz-Luque, J.; Ros, J.; Fernandez-Varo, G.; et al., (2008): Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. *J Pharmacol Exp Ther* ;324:475–483.

Myung, S.J.; Yoon, J.H.; Gwak, G.Y.; et al., (2007): Wnt signaling enhances the activation and survival of human hepatic stellate cells. *FEBS Lett* ;581:2954–2958.

Nakamura, T.; Torimura, T.; Sakamoto, M.; et al., (2007): Significance and therapeutic potential of endothelial progenitor cell transplantation in a cirrhotic liver rat model. *Gastroenterology* ;133: 91–107.

NATALIE, J.T. (2008): Recent advances in the pathogenesis and diagnosis of liver fibrosis. *J Gastroenterol* ; 43:315–321

Neef, M.; Ledermann, M.; Saegesser, H. et al., (2006): Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term. *J Hepatol* ; 44:167.

Nelson, D.R.; Tu, Z.; Soldevila-Pico, C. et al., (2003): Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. *Hepatology* ; 38:859.

Nguyen-Khac, E. (2007): Results and place of fibroscan in the noninvasive diagnosis of hepatic fibrosis. *Rev Med Interne* ;28: 94–102.

Oakley, F.; Meso, M.; Iredale, J.P. et al., (2005): Inhibition of inhibitor of kappaB kinases stimulates hepatic stellate cell apoptosis and accelerated recovery from rat liverfibrosis. *Gastroenterology* ; 128:108.

Olaso, E. and Friedman, S.L. (1998): Molecular regulation of hepatic fibrogenesis. *J Hepatol* ; 29: 836–47.

Osterreicher, C.H.; Datz, C.; Stickel F. et al., (2005): TGF-[beta]1 codon 25 gene polymorphism is associated with cirrhosis in patients with hereditary hemochromatosis. *Cytokine*: 31: 142–8.

Ozaki, I.; Zhao, G.; Mizuta, T.; et al., (2002): Hepatocyte growth factor induces collagenase (matrix metalloproteinase-1) via the transcription factor Ets-1 in human hepatic stellate cell line. *J Hepatol* ; 36:169.

Park, G.J.H.; Lin, B.P.C.; Ngu, M.C. et al., (2000): Aspartate aminotransferase: alanine aminotransferase ratio in chronic hepatitis C infection: Is it a useful predictor of cirrhosis? *J Gastroenterol Hepatol.*; 15: 386–90.

Parkes, J.; Guha, I.N.; Roderick, P.; et al., (2006): Performance of serum marker panels for liver fibrosis in chronic hepatitis C. J Hepatol. ; 44: 462–74.

Parsons, C.J.; Bradford, B.U.; Pan, C.Q. et al., (2004): Antifibrotic effects of a tissue inhibitor of metalloproteinase-1 antibody on established liver fibrosis in rats. Hepatology ; 40:1106.

Patel, K.; Gordon, S.C.; Jacobson, I. et al., (2004): Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to advanced liver fibrosis in chronic hepatitis C patients. J Hepatol.; 41: 935–42.

Pinzani, M. and Vizzutti, F. (2008): Fibrosis and Cirrhosis Reversibility: Clinical Features and Implications Clin Liver Dis 12 ; 901–913.

Pockros, P.J.; Jeffers, L.; Afdhal, N. et al., (2007): Final results of a double-blind, placebocontrolled trial of the antifibrotic efficacy of interferon gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. Hepatology ; 45:569.

Pockros, P.J.; Schiff, E.R.; Shiffman, M.L.; et al., (2007): Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower amino transferase activity in patients with chronic hepatitis C. Hepatology ;46:324–329.

Pohl, A.; Behling, C.; Oliver, D. et al., (2001): Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol.; 96: 3142–6.

Pol, S.; Carnot, F.; Nalpas, B. et al., (2004): Reversibility of hepatitis C virus-related cirrhosis. Hum Pathol ;35:107–112.

Popper, H and Uenfriend, S. (1970): Hepatic fibrosis. Correlation of biochemical and morphologic investigations. *Am J Med*; 49: 707–21.

Poynard, T.; Imbert-Bismut, F.; Munteanu, M. et al., (2004): Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. *Comp Hepatol.* ; 3: 8.

Poynard, T.; Imbert-Bismut, F.; Munteanu, M.; et al., (2004): Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. *Comp Hepatol.* ; 3: 8.

Poynard, T.; McHutchison, J.; Manns, M. et al., (2003): Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. *Hepatology.* ; 38: 481–92.

Radaeva, S.; Sun, R.; Jaruga, B.; et al., (2006): Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D dependent and tumor necrosis factor-related apoptosis-inducing ligand dependent manners. *Gastroenterology* ; 130:435.

Radaeva, S.; Wang, L.; Radaev, S.; et al., (2007): Retinoic acid signaling sensitizes hepatic stellate cells to NK cell killing via upregulation of NK cell activating ligand RAE1. *Am J Physiol* ;293: G809–G816.

Ramalho, L.N.; Ramalho, F.S.; Zucoloto, S. et al., (2002): Effect of losartan, an angiotensin II antagonist, on secondary biliary cirrhosis. *Hepatogastroenterology* ; 49:1499.

- Rambaldi, A. & Gluud, C. (2001):** Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. Cochrane Database Syst Rev ;CD002148.
- Ratziu, V.; Giral, P.; Munteanu, M.; et al., (2007):** Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia. Aliment Pharmacol Ther. ; 25: 207–18.
- Reynaert, H.; Thompson, M.G.; Thomas, T.; et al., (2002):** Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension. Gut ;50:571–581.
- Rockey, D.C. (2003):** Vascular mediators in the injured liver. Hepatology ;37:4–12.
- Rockey, D.C. (2005):** Antifibrotic therapy in chronic liver disease. Clin. Gastroenterol. Hepatol. ; 3: 95–107.
- Rockey, D.C. (2007):** Noninvasive Assessment of Liver Fibrosis and Portal Hypertension with Transient Elastography. j.gastro;11.053
- Rockey, D.C. (2008):** Noninvasive assessment of liver fibrosis and portal hypertension with transient elastography. Gastroenterology ;134:8–14.
- Roderfeld, M.; Weiskirchen, R.; Wagner, S.; et al., (2006):** Inhibition of hepatic fibrogenesis by matrix metalloproteinase-9 mutants in mice. FASEB J ;20:444–454.
- Rosenthal-Allieri, M.A.; Peritore, M.L.; Tran, A.; et al., (2005):** Analytical variability of the Fibrotest proteins. Clin Biochem. ; 38: 473–8.
- Roskams, T. (2006):** Different types of liver progenitor cells and their niches. J Hepatol ;45:1– 4.

Roulot, D.; Czernichow, S.; Le Clesiau, H. et al., (2008): Liver stiffness values in apparently healthy subjects: Influence of gender and metabolic syndrome. *J Hepatol* ; 48(4): 606–613.

Rovida, E.; Navari, N.; Caligiuri, A.; et al., (2008): ERK5 differentially regulates PDGF-induced proliferation and migration of hepatic stellate cells. *J Hepatol* ;48:107–115.

Russo, F.P.; Kallis, Y.N.; Alison, M.R.; et al., (2007): Bone marrow cells in the liver: diverse cells, diverse effects. *Hepatology* ;46:604–5.

Saab, S.; Tam, S.P.; Tran, B.N.; et al., (2002): Myosin mediates contractile force generation by hepatic stellate cells in response to endothelin- 1. *J Biomed Sci* ;9:607–612.

Safadi, R.; Ohta, M.; Alvarez, C.E.; et al., (2004): Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin 10 from hepatocytes. *Gastroenterology* ; 127:870–882.

Sanada, M.; Ebara, M.; Fukuda, H. et al. (2000): Clinical evaluation of sonoelasticity measurement in liver using ultrasonic imaging of internal forced low-frequency vibration. *Ultrasound Med Biol*;26:1455–1460.

Sancho-Bru, P.; Bataller, R.; Fernandez-Varo, G. et al., (2007): Bradykinin attenuates hepatocellular damage and fibrosis in rats with chronic liver injury. *Gastroenterology* ; 133:2019.

Sandrin, L.; Fourquet, B.; Hasquenoph, J.M. et al., (2003): Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. *Ultrasound Med Biol* ; 29(12): 1705–1713.

Sato, Y.; Murase, K.; Kato, J.; et al., (2008): Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. *Nat Biotechnol* ; 26:431.

Schaefer, B.; Rivas-Estilla, A.M.; Meraz-Cruz, N.; et al., (2003): Reciprocal modulation of matrix metalloproteinase-13 and type I collagen genes in rat hepatic stellate cells. *Am J Pathol* ;162: 1771–1780.

Schneider, A.R.; Teuber, G.; Kriener, S. et al., (2005): Non-invasive assessment of liver steatosis, fibrosis and inflammation in chronic hepatitis C virus infection. *Liver Int* ;25:1150–1155.

Schuppan D., Ruehl M., Somasundaram R., et al. (2001): Matrix as a modulator of hepatic fibrogenesis. *Semin. Liver Dis.*; 21: 351-372.

Sebastiani, G.; Vario, A.; Guido, M.; et al., (2006): Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. *J Hepatol.* ; 44: 686–93.

Seef, L.B. and Lie B.A. (2005): Is cirrhosis an inevitable consequence of chronic hepatitis C infection? *Clin Gastroenterol Hepatol* ;3:840–2.

Serpaggi, J.; Carnot, F.; Nalpas, B.; et al., (2006): Direct and indirect evidence for the reversibility of cirrhosis. *Hum Pathol*;37:1519–26.

Shafiei, M.S. and Rockey, D.C. (2006): The role of integrin-linked kinase in liver wound healing. *J Biol Chem* ;281:24863–24872.

Shen, L.; Li, J.Q.; Zeng, M.D. et al., (2006): Correlation between ultrasonographic and pathologic diagnosis of liver fibrosis due to chronic virus hepatitis. *World J Gastroenterol* ;12:1292–1295.

Sheth, S.G.; Flamm, S.L.; Gordon, F.D. et al., (1998): AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. *Am J Gastroenterol.* ; 93: 44–8.

Shimizu, I.; Ma, Y.R.; Mizobuchi, Y. et al., (1999): Effects of Sho-saiko-to, a Japanese herbal medicine, on hepatic fibrosis in rats. *Hepatology* ; 29:149.

Siller-Lopez, F.; Sandoval, A.; Salgado, S. et al., (2004): Treatment with human metalloproteinase-8 gene delivery ameliorates experimental rat liver cirrhosis. *Gastroenterology* ; 126:1122.

Singer, A.J.; Clark, R.A.; Singer, I.I.; et al., (1999): Cutaneous wound healing. *N Engl J Med* ; 341: 738–46.

Smart, D.E.; Green, K.; Oakley, F.; et al., (2006): JunD is a profibrogenic transcription factor regulated by Jun N-terminal kinase-independent phosphorylation. *Hepatology*; 44:1432–1440.

Smith, B.C.; Grove, J.; Guzail, M.A. et al., (1998): Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. *Hepatology.*; 27: 1695–9.

Solga, S.F.; Horska, A.; Clark, J.M. Et al., (2005): Hepatic 31P magnetic resonance spectroscopy: a hepatologist's user guide. *Liver Int* ;25:490-500.

Sonzogni, L.; Silvestri, L.; De Silvestri, A. et al., (2002): Polymorphisms of microsomal epoxide hydrolase gene and severity of HCV-related liver disease. *Hepatology.* ; 36: 195–201.

- Stefanovic, L.; Stephens, C.E.; Boykin, D. et al., (2005):** Inhibitory effect of dicationic diphenylfurans on production of type I collagen by human fibroblasts and activated hepatic stellate cells. *Life Sci* ; 76:2011.
- Sterling, R.K.; Lissen, E.; Clumeck, N. et al., (2006):** Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. *Hepatology.*; 43: 1317–25.
- Sud, A.; Hui, J.M.; Farrell, G.C. et al., (2004):** Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. *Hepatology.* ; 39: 1239–47.
- Sugimoto, H.; Yang, C.; LeBleu, V.S.; et al., (2007):** BMP-7 functions as a novel hormone to facilitate liver regeneration. *FASEB J* ;21:256–64.
- Susanne, B.; Ihab, K.; Steven, S. et al., (2009):** Can imaging modalities diagnose and stage hepatic fibrosis and cirrhosis accurately?. *Journal of Hepatology* ;50:17–35.
- T.P.; Presson, T.L.; Heneghan, M.A.; et al., (2003):** Transjugular biopsy of the liver in pediatric and adult patients using an 18-gauge automated core biopsy needle: a retrospective review of 410 consecutive procedures. *AJR Am J Roentgenol* ;180:167–172.
- Tacke, F.; Gäbele, E.; Bataille, F. et al., (2007):** Bone morphogenetic protein 7 is elevated in patients with chronic liver disease and exerts fibrogenic effects on human hepatic stellate cells. *Dig Dis Sci*.
- Talwalkar, J.A.; Yin, M.; Fidler, J.L. et al., (2008):** Magnetic resonance imaging of hepatic fibrosis: emerging clinical applications. *Hepatology* ;47:332–342.

Tanaka, A.; Quaranta, S.; Mattalia, A. et al., (1999): The tumor necrosis factor-[alpha] promoter correlates with progression of primary biliary cirrhosis. *J Hepatol.* ; 30: 826–9.

Taylor-Robinson S.D. (2001): Applications of magnetic resonance spectroscopy to chronic liver disease. *Clin Med* ;1:54-60.

Tchelepi, H.; Ralls, P.W.; Radin, R. et al., (2002): Sonography of diffuse liver disease. *J Ultrasound Med* ;21:1023–1032.

Teare, J.P.; Greenfield, S.M.; Thompson, R.P.H. et al., (1993): Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis. *The Lancet.* ; 342: 895–8.

Teixeira-Clerc, F.; Julien, B.; Grenard, P.; et al., (2006): CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. *Nat Med* ;12:671–676.

Testa, R.; Testa, E.; Giannini, E. et al., (2006): Noninvasive ratio indexes to evaluate fibrosis staging in chronic hepatitis C: role of platelet count/spleen diameter ratio index. *J Intern Med.*; 260: 142-50.

Thomasson, H.R.; Crabb, D.W.; Edenberg, H.J. et al., (1994): Low Frequency of the ADH2*2 Allele among Atayal Natives of Taiwan with Alcohol Use Disorders. *Alcohol Clin Exp Res.*; 18: 640–3.

Tsukada, S.; Parsons, C.J. and Rippe, R.A. (2006): Mechanisms of liver fibrosis. *Clin Chim Acta* ;364:33–60.

Tugues, S.; Fernandez-Varo, G.; Munoz-Luque, J.; et al., (2007): Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. *Hepatology* ;46:1919–1926.

Valencia-Sanchez, M.A.; Liu, J.; Hannon, G.J.; et al., (2006): Control of translation and mRNA degradation by miRNAs and siRNAs. *Genes Dev* ;20:515–524.

Valentino, K.L.; Gutierrez, M.; Sanchez, R. et al., (2003): First clinical trial of a novel caspase inhibitor: anti-apoptotic caspase inhibitor, IDN-6556, improves liver enzymes. *Int J Clin Pharmacol Ther*;41:441.

Van leeuwen MS, Noordzij J, Fernandez MA et al., (1994): Portal venous and segmental anatomy of the right hemiliver: observations based on three-dimensional spiral CT renderings. *Am. J. Roentgenol.*; 163:1395.

Vizzutti, F.; Arena, U.; Romanelli, R.G.; et al., (2007): Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. *Hepatology* ;45:1290–1297

Wasser, S.; Ho, J.M.; Ang, H.K. et al., (1998): *Salvia miltiorrhiza* reduces experimentally induced hepatic fibrosis in rats. *J Hepatol* ; 29:760.

Watanabe, A.; Hashmi, A.; Gomes, D.A.; et al., (2007): Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via Toll-like receptor 9. *Hepatology* ;46:1509–1518.

Wells, R.G. (2008): The role of matrix stiffness in regulating cell behavior. *Hepatology* ;47:1394–1400.

Wiercinska, E.; Wickert, L.; Denecke, B.; et al., (2006): Id1 is a critical mediator in TGF-beta-induced transdifferentiation of rat hepatic stellate cells. *Hepatology* ;43:1032–1041.

Winnock M., Garcia Barcina M., Lukomska B., et al. (1995): Human liver-associated lymphocytes: an overview. *J. Gastroenterol. Hepatol.*; 10: S43-S46.

- Wu, J.A. & Danielsson, A.(1995):** Detection of hepatic fibrogenesis: A review of available techniques. Scand J
- Yang, C.; Zeisberg, M.; Mosterman, B.; et al., (2003):** Liver fibrosis: insights into migration of hepatic stellate cells in response to extracellular matrix and growth factors. Gastroenterology ;124: 147–159.
- Yin, M.; Talwalkar, J.A.; Glaser, K.J. et al., (2007):** Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastro Hep ;5:1207-1213.
- Yoshiji, H.; Kuriyama, S.; Noguchi, R. et al., (2006):** Amelioration of liver fibrogenesis by dual inhibition of PDGF and TGF-beta with a combination of imatinib mesylate and ACE inhibitor in rats. Int J Mol Med ; 17:899.
- Yoshiji, H.; Kuriyama, S.; Yoshii, J. et al., (2002):** Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse. Hepatology ; 36:850.
- Zeisberg, M.; Yang, C.; Martino, M.; et al., (2007):** Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem ;282:23337–23347.
- Zhang, Y. & Edwards, P.A. (2008):** FXR signaling in metabolic disease. FEBS Lett ; 582:10.
- Zheng, S. & Chen, A. (2007):** Disruption of transforming growth factor-beta signaling by curcumin induces gene expression of peroxisome proliferator-activated receptor gamma in rat hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol ; 292:G113.